TABLE 2.

Clinicopathological findings of non-AML myeloid neoplasm patients with NPM1 mutations based on mNPM1 Immunohistochemistry.

	NPM1 IHC positive	NPM1 IHC negative	p value
Diagnosis	15	16
	• 10 MDS	• 9 MDS
	• 5 non-MDS	• 7 non-MDS
BM blasts	7% (median)	2% (median)	0.01a
NPM1 mutation	c.859C > T mutation: 3 cases	c.859C > T mutation: 16 cases	<0.001b
	Insertion or duplication: 12 cases
VAF%	18.9% (median)	8.06% (median)	0.01a
Progress to AML	5/15 (33%)	4/16 (25%)
Abnormal karyotype	6/15 (40%)	5/15 (33%)
Survival	20 months (median)	48 months (median)

^at-test.

^bChi-square test.